The Cannabis Industry’s Medical Pivot: Why Most Companies Are Already Ten Years Ahead
The cannabis industry medical pivot reflects a strategic shift toward research infrastructure and pharmaceutical-grade manufacturing. Many companies are positioning themselves ahead of regulatory changes and DEA research licensing expansion. This pivot…
Cocaine and Cannabis Use Elevates Stroke Risk Significantly
Cocaine cannabis stroke risk significantly increases the likelihood of strokes, especially in younger patients. Clinicians should assess substance use patterns to identify modifiable risk factors. Counseling about stroke risk is essential for patients…
Recreational Drugs and Stroke Risk: Clinical Evidence on Cannabis
Cannabis stroke risk clinical evidence indicates a 37% increased risk of stroke among users. This finding is critical for stroke prevention strategies, especially in younger populations. Clinicians should integrate cannabis use screening into…
Study Highlights Stroke Risk Linked to Recreational Drugs, Including Among Young Users
This study highlights cannabis stroke risk young users face, revealing significant cerebrovascular dangers linked to recreational drug use. Clinicians should incorporate cannabis use history into stroke risk assessments, especially for younger patients.…
Daily Digest: Last 9 Hours: Stroke Risk From Recreational Drugs and DEA Scheduling Actions — March 08, 2026
A synthesis of 12 recently added cannabis articles — key themes, clinical context, and Dr. Caplan's take.
Daily Cannabis News Digest: Top Updates March 8, 2026
This daily cannabis news digest provides top updates from the cannabis industry and research pipeline. Stay informed on medical cannabis news and policy developments. Our digest covers key highlights from March 8, 2026.
Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I
The DEA temporary placement Schedule I of N-Desethyl Isotonitazene reflects efforts to control emerging synthetic opioids. This scheduling targets substances with no recognized medical use. Clinicians should stay updated on DEA temporary placement…
Importer of Controlled-Biopharmaceutical (2024-20085) DEA1425 Notice
Controlled biopharmaceutical regulations 2024 are essential for importers to maintain DEA compliance. This notice outlines important regulatory updates affecting controlled substance importers. Understanding these regulations supports adherence to…
Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I
Nitazene synthetic opioids such as N-pyrrolidino metonitazene and N-pyrrolidino protonitazene have been temporarily placed in Schedule I. These substances pose significant overdose risks and are emerging threats in illicit drug supplies. Clinicians…
Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I
This article discusses the schedules of controlled substances focusing on ethylphenidate's placement in Schedule I. The scheduling reflects concerns about synthetic stimulants and abuse potential. Clinicians should be aware of regulatory updates on…
